Can New Generation GLP-1s Overcome The Adherence Hurdle?

Historically, Patients Have Not Tended To Stay On These Drugs Long-Term

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term. 

Pair of hands holding semaglutide injection pen
Patients taking Wegovy lost an average of 15.2% of their body weight in clinical trials • Source: Shutterstock

Stocks at Novo Nordisk A/S and Eli Lilly and Company took a tumble in July after an analysis by pharmacy benefit manager Prime Therapeutics revealed that most patients taking GLP-1 receptor agonists, like semaglutide, discontinue treatment after a year. The report is the latest in a growing body of evidence which indicates that, despite the never-before-seen weight loss efficacy of these medicines, patient adherence could be a significant hurdle when it comes to long term market success for the new generation of weight loss drugs.

Novo And Lilly Are At The Forefront Of The Weight Loss Drug Revolution

Novo Nordisk manufactures the two most prolific GLP-1 products available, both of which are injectable semaglutide products. The first, Ozempic, is indicated as an adjunct to diet and exercise to help improve glycemic control in adult patients with type 2 diabetes. It is also indicated to reduce the risk of major cardiovascular events in type 2 diabetics with an established cardiovascular disease. Meanwhile, Wegovy is indicated for weight management of obese or overweight adult patients with at least one weight-related condition, alongside a reduced calorie diet and increased physical activity. Patients taking Wegovy lost an average of 15.2% of their body weight in clinical trials.

A challenger has recently arrived to Novo Nordisk’s semaglutide supremacy in the form of Eli Lilly’s Mounjaro, which was approved by the US FDA with a diabetes indication last year. Mounjaro, likewise a weekly injection, induced weight loss of up to 15.7% in a recent clinical trial. (Also see "Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market" - Scrip, 27 April, 2023.)

Prime Therapeutics reviewed pharmacy and medical claims data for 4,255 people with commercial health plans who received new prescriptions of...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Intelligence

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketIntelligence (Premium-2): Neuroanatomy of the Cerebral Cortex: Structure, Function, and Significance

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By Nabil

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By David Wild

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting